N'-Methyl-o-tolyl-hydrazin | 133711-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N'-Methyl-o-tolyl-hydrazin
• 英文别名: 1-Methyl-2-(2-methylphenyl)hydrazine
• CAS: 133711-40-7
• 化学式: C₈H₁₂N₂
• 分子量: 136.197
• InChiKey: ZHZQUXWDHQHYGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• CRTH2 Receptor Ligands For Medicinal Uses
  申请人：Ulven Trond

  公开号：US20090099189A1

  公开（公告）日：2009-04-16

  Compounds of formula (I) are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis, wherein A represents a carboxyl group —COON, or a carboxyl bioisostere; A 1 , is hydrogen or methyl; ring Ar 1 is an optionally substituted phenyl ring 5- or 6-membered monocyclic heteroaryl ring, in which AA 1 CHO— and L2 are linked to adjacent ring atoms; rings Are 2 , Ar 3 each independently represent a phenyl or 5- or 6-membered monocyclic heteroaryl ring, or a bicyclic ring system consisting of a 5- or 6-membered carbocyclic or heterocyclic ring which is benz-fused or fused to a 5- or 6-membered monocyclic heteroaryl ring, said ring or ring system being optionally substituted; t is 0 or 1; L2 and L3 are linker radicals as defined in the description.

  式(I)的化合物可用于治疗对CRTH2受体活性调节敏感的疾病，例如哮喘、鼻炎、过敏性气道综合症和过敏性鼻支气管炎，其中A代表羧基—COON或羧基生物同位素；A1为氢或甲基；环Ar1是一个可选取代的苯环5-或6-成员的单环杂环，其中AA1CHO—和L2与相邻的环原子连接；环Are2，Ar3各自独立地表示一个苯环或5-或6-成员的单环杂环，或由一个5-或6-成员的碳环或杂环组成的双环系统，该环或环系统被苯并或与一个5-或6-成员的单环杂环融合，该环或环系统是可选取代的；t为0或1；L2和L3是如描述中所定义的连接基团。
• [EN] ALDEHYDE DEHYDROGENASE INHIBITORS AND THEIR THERAPEUTIC USE<br/>[FR] INHIBITEURS D'ALDÉHYDE DÉSHYDROGÉNASE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：CANCER RESEARCH TECH LTD

  公开号：WO2022123039A1

  公开（公告）日：2022-06-16

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain aldehyde dehydrogenase inhibitor compounds (also referred to herein as "ALDHI compounds"), that, inter alia, inhibit aldehyde dehydrogenase enzyme ALDH1A3. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, bothin vitroandin vivo, to inhibit ALDH1A3 enzyme; to treat disorder (e.g., diseases) that are ameliorated by the inhibition of ALDH1A3 enzyme; to treat a proliferative disorder, cancer, obesity, diabetes, a cardiovascular disorder, etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些醛脱氢酶抑制剂化合物（在此称为“ALDHI化合物”），这些化合物可以抑制醛脱氢酶酶ALDH1A3，从而治疗和改善由ALDH1A3酶抑制引起的疾病。本发明还涉及包含这些化合物的制药组合物，以及在体内外使用这些化合物和组合物来抑制ALDH1A3酶，治疗增殖性疾病、癌症、肥胖症、糖尿病、心血管疾病等疾病。
• CRTH2 RECEPTOR LIGANDS FOR MEDICINAL USES
  申请人：7TM Pharma A/S

  公开号：EP1758579A1

  公开（公告）日：2007-03-07
• US3931268A
  申请人：——

  公开号：US3931268A

  公开（公告）日：1976-01-06
• US8022063B2
  申请人：——

  公开号：US8022063B2

  公开（公告）日：2011-09-20